Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.

PHASE3CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Choroidal Neovascularization (CNV)
Interventions
DRUG

Ranibizumab

Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.

OTHER

Sham control

The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.

Trial Locations (59)

27

Novartis Investigative Site, San Isidro

1002

Novartis Investigative Site, Riga

1007

Novartis Investigative Site, Lausanne

1083

Novartis Investigative Site, Budapest

1133

Novartis Investigative Site, Budapest

2000

Novartis Investigative Site, Sydney

2600

Novartis Investigative Site, Glostrup Municipality

3010

Novartis Investigative Site, Bern

4012

Novartis Investigative Site, Debrecen

4043

Novartis Investigative Site, Debrecen

4102

Novartis Investigative Site, Binningen

5000

Novartis Investigative Site, Adelaide

7249

Novartis Investigative Site, South Launceston

20132

Novartis Investigative Site, Milan

21100

Novartis Investigative Site, Varese

29010

Novartis Investigative Site, Málaga

33100

Novartis Investigative Site, Udine

34420

Novartis Investigative Site, Istanbul

40225

Novartis Investigative Site, Düsseldorf

41380

Novartis Investigative Site, Kocaeli

44892

Novartis Investigative Site, Bochum

47011

Novartis Investigative Site, Valladolid

48145

Novartis Investigative Site, Münster

48149

Novartis Investigative Site, Münster

50009

Novartis Investigative Site, Kaunas

53127

Novartis Investigative Site, Bonn

70124

Novartis Investigative Site, Bari

72076

Novartis Investigative Site, Tübingen

75010

Novartis Investigative Site, Paris

79106

Novartis Investigative Site, Freiburg I. Br

91171

Novartis Investigative Site, Trenčín

93042

Novartis Investigative Site, Regensburg

95123

Novartis Investigative Site, Catania

97517

Novartis Investigative Site, Banská Bystrica

119021

Novartis Investigative Site, Moscow

127486

Novartis Investigative Site, Moscow

168751

Novartis Investigative Site, Singapore

420012

Novartis Investigative Site, Kazan'

H1T 2M4

Novartis Investigative Site, Montreal

505 05

Novartis Investigative Site, Hradec Králové

100 34

Novartis Investigative Site, Prague

F-75571

Novartis Investigative Site, Paris

04103

Novartis Investigative Site, Leipzig

265 00

Novartis Investigative Site, Pátrai

GR 56429

Novartis Investigative Site, Thessaloniki

711 10

Novartis Investigative Site, Heraklion Crete

H-6720

Novartis Investigative Site, Szeged

00198

Novartis Investigative Site, Roma

LT-08661

Novartis Investigative Site, Vilnius

40-594

Novartis Investigative Site, Katowice

50-556

Novartis Investigative Site, Wroclaw

3000-354

Novartis Investigative Site, Coimbra

4200-319

Novartis Investigative Site, Porto

602-739

Novartis Investigative Site, Busan

03080

Novartis Investigative Site, Seoul

06591

Novartis Investigative Site, Seoul

150-034

Novartis Investigative Site, Seoul

08190

Novartis Investigative Site, Sant Cugat del Vallès

06100

Novartis Investigative Site, Ankara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY